Highlights from the International Transporter Consortium Second Workshop

MJ Zamek-Gliszczynski\textsuperscript{1}, KA Hoffmaster\textsuperscript{2}, DJ Tweedie\textsuperscript{3},
KM Giacomini\textsuperscript{4} and KM Hillgren\textsuperscript{1,\ast}

The Second International Transporter Consortium (ITC) Workshop was held with the purpose of expanding on previous white-paper recommendations, discussing recent regulatory draft guidance documents on transporter–drug interactions, and highlighting transporter-related challenges in drug development. Specific goals were to discuss additional clinically relevant transporters (MATEs, MRP2, BSEP) and best-practice methodologies and to re-evaluate ITC decision trees based on actual case studies. The outcome of the workshop will be a series of white papers targeted for publication in 2013.


- Emerging transporters of clinical importance
- Transport IVIVE/PK best practices
- Transporter pharmacogenomics
- Brain distribution: no to low risk of clinical drug interactions
- Transport in vitro methods best practices
- Intracellular drug concentrations and transporters
- Transporters in drug development: regulatory and industrial perspectives